These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 11282080

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Comparative mechanisms of antiarrhythmic drug action in experimental atrial fibrillation. Importance of use-dependent effects on refractoriness.
    Wang J, Bourne GW, Wang Z, Villemaire C, Talajic M, Nattel S.
    Circulation; 1993 Sep; 88(3):1030-44. PubMed ID: 8353865
    [Abstract] [Full Text] [Related]

  • 5. Contrasting efficacy of dofetilide in differing experimental models of atrial fibrillation.
    Li D, Bénardeau A, Nattel S.
    Circulation; 2000 Jul 04; 102(1):104-12. PubMed ID: 10880422
    [Abstract] [Full Text] [Related]

  • 6. Effects of the novel antiarrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic properties.
    Nattel S, Liu L, St-Georges D.
    Cardiovasc Res; 1998 Mar 04; 37(3):627-35. PubMed ID: 9659446
    [Abstract] [Full Text] [Related]

  • 7. The pharmacological response of ischemia-related atrial fibrillation in dogs: evidence for substrate-specific efficacy.
    Rivard L, Sinno H, Shiroshita-Takeshita A, Schram G, Leung TK, Nattel S.
    Cardiovasc Res; 2007 Apr 01; 74(1):104-13. PubMed ID: 17316585
    [Abstract] [Full Text] [Related]

  • 8. New antiarrhythmic agents for atrial fibrillation and atrial flutter: United States drug market response as an indicator of acceptance.
    LaPointe NM, Pamer CA, Kramer JM.
    Pharmacotherapy; 2003 Oct 01; 23(10):1316-21. PubMed ID: 14594348
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cardioversion of persistent atrial fibrillation by a combination of atrial specific and non-specific class III drugs in the goat.
    Blaauw Y, Schotten U, van Hunnik A, Neuberger HR, Allessie MA.
    Cardiovasc Res; 2007 Jul 01; 75(1):89-98. PubMed ID: 17466958
    [Abstract] [Full Text] [Related]

  • 11. Effects of antiarrhythmic drugs on fibrillation in the remodeled atrium: insights into the mechanism of the superior efficacy of amiodarone.
    Shinagawa K, Shiroshita-Takeshita A, Schram G, Nattel S.
    Circulation; 2003 Mar 18; 107(10):1440-6. PubMed ID: 12642367
    [Abstract] [Full Text] [Related]

  • 12. Dofetilide: a review of its use in atrial fibrillation and atrial flutter.
    McClellan KJ, Markham A.
    Drugs; 1999 Dec 18; 58(6):1043-59. PubMed ID: 10651390
    [Abstract] [Full Text] [Related]

  • 13. A multicentre, double-blind randomized crossover comparative study on the efficacy and safety of dofetilide vs sotalol in patients with inducible sustained ventricular tachycardia and ischaemic heart disease.
    Boriani G, Lubinski A, Capucci A, Niederle R, Kornacewicz-Jack Z, Wnuk-Wojnar AM, Borggrefe M, Brachmann J, Biffi M, Butrous GS, Ventricular Arrhythmias Dofetilide Investigators.
    Eur Heart J; 2001 Dec 18; 22(23):2180-91. PubMed ID: 11913480
    [Abstract] [Full Text] [Related]

  • 14. A review of class III antiarrhythmic agents for atrial fibrillation: maintenance of normal sinus rhythm.
    Tsikouris JP, Cox CD.
    Pharmacotherapy; 2001 Dec 18; 21(12):1514-29. PubMed ID: 11765303
    [Abstract] [Full Text] [Related]

  • 15. Comparison in the same patient of aberrant conduction and bundle branch reentry after dofetilide, a new selective class III antiarrhythmic agent.
    Crijns HJ, Kingma JH, Gosselink AT, Lie K.
    Pacing Clin Electrophysiol; 1993 May 18; 16(5 Pt 1):1006-16. PubMed ID: 7685880
    [Abstract] [Full Text] [Related]

  • 16. Effects of EGIS-7229 (S 21407), a novel class III antiarrhythmic drug, on myocardial refractoriness to electrical stimulation in vivo and in vitro.
    Kovács A, Gyönös I, Magyar J, Bányász T, Nánási PP, Spedding M, Szénási G.
    J Cardiovasc Pharmacol; 2001 Jan 18; 37(1):78-88. PubMed ID: 11152377
    [Abstract] [Full Text] [Related]

  • 17. Consequences of atrial electrical remodeling for the anti-arrhythmic action of class IC and class III drugs.
    Duytschaever M, Blaauw Y, Allessie M.
    Cardiovasc Res; 2005 Jul 01; 67(1):69-76. PubMed ID: 15949471
    [Abstract] [Full Text] [Related]

  • 18. Synergistic Effect of Dofetilide and Mexiletine on Prevention of Atrial Fibrillation.
    Liu G, Xue X, Gao C, Huang J, Qi D, Zhang Y, Dong JZ, Ma CS, Yan GX.
    J Am Heart Assoc; 2017 May 18; 6(5):. PubMed ID: 28522677
    [Abstract] [Full Text] [Related]

  • 19. Electrophysiological effects of flecainide and sotalol in the human atrium during persistent atrial fibrillation.
    Kirchhof P, Engelen M, Franz MR, Ribbing M, Wasmer K, Breithardt G, Haverkamp W, Eckardt L.
    Basic Res Cardiol; 2005 Mar 18; 100(2):112-21. PubMed ID: 15696400
    [Abstract] [Full Text] [Related]

  • 20. Effects of procainamide and dl-sotalol on the changes of atrial electrophysiology induced by high current stimulation.
    Yu WC, Chen SA, Tai CT, Wen ZC, Feng AN, Ding YA, Chang MS.
    Pacing Clin Electrophysiol; 1998 Nov 18; 21(11 Pt 1):2064-9. PubMed ID: 9826857
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.